<?xml version="1.0"?>

<document>
	<title>Serum complement depression during viral lower respiratory tract
   illness in cystic fibrosis.</title>

	<author>Strunk-R-C.</author>
	<author>Sieber-O-F.</author>
	<author>Taussig-L-M.</author>
	<author>Gall-E-P.</author>

	<source>Arch-Dis-Child. 1977 Sep. 52(9). P 687-90.</source>

	<abstract>Cystic fibrosis (CF) patients with viral lower respiratory tract
   illnesses (LRI) had depressed levels of the third and fourth
   components of complement, which returned to normal after recovery.
   There was no clinical evidence of immune complex disease. CF patients
   with LRI and no virus isolates, CF patients in stable status, and non-
   CF patients with LRI did not have complement depression. It is
   postulated that antigen-antibody complex activation of complement may
   occur in CF patients with viral LRI.</abstract>

	<majorsubject>COMPLEMENT: an</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: co</majorsubject>
	<majorsubject>RESPIRATORY-TRACT-INFECTIONS: im</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CHILD-PRESCHOOL</minorsubject>
	<minorsubject>COMPLEMENT-3: an</minorsubject>
	<minorsubject>COMPLEMENT-4: an</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: im</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>INFANT</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>RESPIRATORY-TRACT-INFECTIONS: co</minorsubject>
	<minorsubject>SUPPORT-U-S-GOVT-P-H-S</minorsubject>
	<minorsubject>VIRUS-DISEASES: im</minorsubject>

	<reference>001   CONOVER JH            LANCET                           2  1501 973</reference>
	<reference>002   DEFOREST A            PEDIATR RES                      6   388 972</reference>
	<reference>003   GAITHER TA            J IMMUNOL                      113   574 974</reference>
	<reference>004   HANN S                LANCET                           2   520 974</reference>
	<reference>005   LENNETTE EH           DIAGN PROCEDURES FOR VIRAL AN            969</reference>
	<reference>006   MCFARLANE H           BR MED J                         1   423 975</reference>
	<reference>007   MANCINI G             IMMUNOCHEMISTRY                  2   235 965</reference>
	<reference>008   MAYER MM              IN: KABAT EA                         133 961</reference>
	<reference>009   NADLER HL             IN: STANBURY JB                     1683 978</reference>
	<reference>010   OLDSTONE MBA          PROG MED VIROL                  19    84 975</reference>
	<reference>011   POLLEY MJ             J MED GENET                     11   249 974</reference>
	<reference>012   STEIN AA              J PEDIATR                       65   495 964</reference>
	<reference>013   TAUSSIG LM            J PEDIATR                       82   380 973</reference>
	<reference>014   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974</reference>

	<citation>1   HOWIE AD              SCOTT MED J                     24   193 979</citation>
	<citation>2   STRAUSS RG            HELV PAEDIATR ACTA              34   429 979</citation>
	<citation>3   MOSS RB               AM REV RESPIR DIS              121    23 980</citation>
	<citation>4   PETERSEN NT           ACTA PAEDIATR SCAND             70   623 981</citation>
	<citation>5   CHURCH JA             CHEST                           80   405 981</citation>
	<citation>6   MANTHEI U             AM REV RESPIR DIS              126   253 982</citation>
	<citation>7   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982</citation>
	<citation>8   GUPTA AK              BR J OPHTHALMOL                 68   350 984</citation>
	<citation>9   SEN DK                BR J OPHTHALMOL                 69   707 985</citation>
	<citation>10   FRIEND PA             J INFECT                        13    55 986</citation>

</document>
